Richard T Maziarz
Hematology — Oregon Health and Science University Hospital, United States
Richard T Maziarz
LeadR Profile
Hematology
Subspecialties: Transplantation - Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 633
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models. cells, hematopoietic stem cell transplantation, lymphoma, b-cell, lymphoma, neoplasms, therapeutics, b-lymphocytes, prognosis, receptors, antigen, t-cell | Transplant Cell Ther | 2026 | 0 |
| Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data. cytokines, cells, precursor cell lymphoblastic leukemia-lymphoma, blood, incidence, hematopoietic stem cell transplantation, lymphoma, lymphoma, large b-cell, diffuse, neurotoxicity syndromes, cytokine release syndrome, receptors, antigen, lymphoma, mantle-cell, receptors, chimeric antigen, transplants, research, therapeutics, t-lymphocytes, receptors, antigen, t-cell | Transplant Cell Ther | 2026 | 0 |
| Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome. cells, incidence, neurotoxicity syndromes, adrenal cortex hormones, therapeutics, hematologic diseases | Blood Adv | 2026 | 0 |
| Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis. cells, mortality, lymphoma, b-cell, lymphoma, receptors, antigen, receptors, chimeric antigen, risk factors, therapeutics, t-lymphocytes, b-lymphocytes, receptors, antigen, t-cell, car-t cell, cytopenia | Blood Adv | 2026 | 1 |
| Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report. cytokines, chromothripsis, cytokine release syndrome, therapeutics | JTO Clin Res Rep | 2026 | 0 |
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU NCT06116110 — cells, genes, hodgkin disease, follow-up studies, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, central nervous system, receptors, antigen, receptors, chimeric antigen, lymphoma, non-hodgkin, therapeutics, nervous system, b-lymphocytes | N/A | Recruiting | 2024 |
| DALY II USA MB CART2019 1 for DLBCL NCT04792489 — cells, safety, hodgkin disease, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, neoplasms, multiple chronic conditions, drug therapy, central nervous system, immunotherapy, central nervous system neoplasms, receptors, antigen, lymphoma, mantle-cell, receptors, chimeric antigen, lymphoma, non-hodgkin, transplants, therapeutics, nervous system, bendamustine hydrochloride, nervous system neoplasms, t-lymphocytes, b-lymphocytes, chemotherapy, car-t cell | Phase 2 | Recruiting | 2021 |
| CRISPR Edited Allogeneic Anti CD19 CAR T Cell Therapy for Relapsed Refractory B Cell Non Hodgkin Lymphoma (ANTLER) NCT04637763 — cells, clustered regularly interspaced short palindromic repeats, hodgkin disease, lymphoma, b-cell, lymphoma, cyclophosphamide, drug therapy, lymphoma, non-hodgkin, therapeutics, t-lymphocytes, b-lymphocytes, chemotherapy, car-t cell | Phase 1 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map